Use of Cetuximab in Combination with Cisplatin and Adjuvant Pelvic Radiation for Stage IIIB Vulvar Carcinoma

Abstract EN

Vulvar cancer is a rare carcinoma constituting only 4% of gynecologic malignancies and 0.6% of female cancers.

Most chemotherapy regimens have been created from extrapolation from anal and cervical cancer research.

Advanced stages have the worst prognosis and oftentimes invasive surgical procedures are needed to cure disease with high recurrence rates.

Case.

A 50 yo G2P2 presented for a 2 cm mass in her right labia.

The patient underwent a partial radical vulvectomy and bilateral superficial and deep inguinal lymph node dissection.

Bilateral inguinal lymph nodes were positive for residual disease.

The patient underwent whole pelvic radiation with cisplatin as a radiosensitizer.

The primary tumor was epidermal growth factor receptor (EGFR) positive and cetuximab, a monoclonal antibody to EGFR, was added.

The patient underwent seven cycles of chemotherapy including cisplatin and cetuximab with adjuvant radiation therapy to the pelvis.

She currently is without evidence of disease recurrence since completing treatment 4 years ago.

Conclusion.

One previous case report showed short-term palliative success of five months for recurrent, metastatic vulvar cancer.

This case suggests that cetuximab could possibly be used in initial management of patients with advanced stages of vulvar cancer to improve prognosis.